Abstract 14268: Comparative Analysis of Postoperative Outcomes Following Surgical vs. Transcatheter Edge-to-Edge Mitral Valve Repair for Secondary Mitral Regurgitation
Abstract
Background: Secondary mitral regurgitation (SMR) remains a significant clinical challenge in patients with left ventricular dysfunction.Surgical mitral valve repair (SMVr) has historically been the standard intervention; however, transcatheter edge-to-edge repair (TEER) has emerged as a less invasive therapeutic alternative for high-risk patients. This meta-analysis evaluates the comparative safety and efficacy of SMVr versus TEER in patients with symptomatic SMR. Methods: Systematic database search identified 3,149 studies reporting on TEER or SMVr for treatment of SMR from inception till May 2024. A total of 10 studies were included after screening according to PRISMA guidelines.Analysis was done using a randome effects model.The outcomes of interest were all-cause mortality,length of hospital stay,cardiovascular outcomes,NYHA functional class improvement, post operative LVEF changes etc. Results: A total of 10 postoperative outcomes and complications were analyzed. Compared to TEER, SMVr was associated with a significantly higher risk of all-cause mortality (RR 1.62, 95% CI 1.17-2.25,p=0.0035) and a longer length of hospital stay (SMD 0.91, 95% CI 0.22-1.60,p=0.0093).SMVr was also associated with increased rates of cardiac arrest (RR 1.52, 95% CI 1.02-2.28,p=0.0417), prolonged mechanical ventilation (RR 1.80, 95% CI 1.12-2.88, p=0.0143), and post-procedural cerebral infarction (RR 2.41;,95% CI 1.30-4.48, p=0.0054).No significant differences were observed between the two groups regarding in-hospital mortality (p=0.5275), cardiac tamponade (p=0.1635), post-procedural thrombosis (p=0.7776), NYHA functional class III/IV at 24 months (p=0.7668) or, post-procedural left ventricular ejection fraction (p=0.5738). Conclusion: In patients with secondary mitral regurgitation, TEER is associated with significantly lower all-cause mortality, shorter hospital stays, and reduced procedural morbidity compared to SMVr.While efficacy endpoints were comparable, TEER's superior safety makes it the preferred intervention for patients at high surgical risk.